# Syngene International (SYNGENE) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/syngene

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹415.25
- Change: +0.28%
- As of: 2026-11-06
- 1D return: +0.28%
- 5D return: +3.12%
- 1M return: +20.01%
- Latest complete quarter: fy27_q2

## Faxioms Analysis

_As of 2026-11-06_

### Technical Outlook

SYNGENE exhibits a sharp, high-conviction daily recovery that contrasts with its longer-term downtrend. As of 2026-11-06, the stock closed at ₹415.25, trading near the upper end of its 20-day and 50-day ranges (+86.1%) while remaining significantly below its 200-day SMA and monthly trend structures. Daily momentum is strong, supported by an ADX of 32.35 and price action above key short-term averages (20/50 EMA/SMA) and the Supertrend. This upward move was fueled by extreme volume anomalies on 2026-10-28 and 2026-10-30, where volume ratios reached 43.5x and 8.22x respectively. However, the weekly trend remains bearish (Supertrend down, ADX 28.54), and the monthly trend is strongly bearish (ADX 55.07). The stock is still in a severe drawdown (-52.8% from available high) with annualized volatility at +32.9%. Immediate resistance lies at ₹417.65 (pivot, +0.58%) and ₹423.15 (high, +1.90%). Support is found at ₹408.60 (-1.60%) and ₹405.90 (-2.25%). A sustained break above ₹423.15 with continued volume would be required to challenge the weekly bearish structure.

- Daily Trend: Bullish and established (ADX 32.35); price above 20/50 EMA/SMA and Supertrend, but below 200-day SMA.
- Momentum & Participation: Extreme volume spikes on 2026-10-28 (43.5x ratio) and 2026-10-30 (8.22x ratio) drove +12.2% and +15.2% range moves.
- Higher-Timeframe Context: Weekly trend is bearish (Supertrend down); Monthly trend is strongly bearish (ADX 55.07, price below all MAs).
- Key Levels: Resistance at ₹417.65 (pivot) and ₹423.15 (high); Support at ₹408.60 and ₹405.90.
- Risk Profile: Current drawdown -52.8%; Annualized volatility +32.9%; Trading near 20-day range highs (+86.1%).

- Outside Bar
- Bullish Engulfing Reversal
- Inside Bar
- Harami

### News Context

On November 2, 2026, media reports indicated that Syngene has appointed a new Chief Executive Officer tasked with initiating a cleanup process following years of operational drift. The reporting suggests that while the leadership change marks a strategic pivot, a full turnaround is expected to require several quarters. This development highlights a significant transition in corporate governance and operational focus for the Indian listed entity.

- New CEO Appointment: A new Chief Executive Officer has been appointed as of early November 2026, signaling a shift in leadership strategy.
- Operational Cleanup: The incoming management is reportedly beginning a cleanup process to address issues stemming from previous operational drift.
- Turnaround Timeline: External analysis indicates that achieving a full operational turnaround may take several quarters, implying a medium-term horizon for stabilization.

- [Syngene's new CEO begins cleanup after years of drift, but turnaround could take several quarters](https://www.moneycontrol.com/news/business/syngene-s-new-ceo-begins-cleanup-after-years-of-drift-but-turnaround-could-take-several-quarters-14066083.html)

### Official Filings

Syngene International Limited reported Q2 FY27 results on October 27, 2026, showing consolidated revenue of ₹8,327 million and profit after tax of ₹322 million. The company highlighted a 13% sequential revenue growth to ₹833 crore and an Operating EBITDA margin improvement of 6 percentage points to 18%. Operational milestones included signing the first manufacturing agreement for the Bayview biologics facility in the U.S., commissioning a new Clinical Translational Sciences Laboratory in Bengaluru, and implementing AI-enabled synthesis planning via ChemVoyager. Concurrently, the Board noted ongoing voluntary liquidation of subsidiary Syngene Manufacturing Solutions Limited (SMSL) and an asset acquisition by Syngene USA Inc. Significant leadership changes were disclosed: CFO Deepak Jain plans to depart after Q3 FY27 results, Head of Strategy Ajay Tandon resigned effective October 30, 2026, and Heads of Chemistry and Biology ceased Senior Management Personnel status on October 27, 2026. Dr. Jayashree Aiyar assumed additional responsibility for Discovery Services effective October 1, 2026.

- Q2 FY27 Consolidated Revenue: ₹8,327 million; Standalone Revenue: ₹7,779 million.
- Q2 FY27 Profit After Tax: ₹322 million (Consolidated); ₹487 million (Standalone).
- Margin Expansion: Operating EBITDA margin improved by 6 percentage points to 18% sequentially.
- Leadership Transition: CFO Deepak Jain departing post-Q3 FY27; Head of Strategy Ajay Tandon resigned effective Oct 30, 2026.

- [SYNGENE INTERNATIONAL LIMITED has informed the Exchange about Transcripts - earnings or quarterly calls |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_12953_WebXMLFile_20261102_175127374.xml)
- [Syngene International Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/SYNGENE2_29102026190829_SEIntimationNewspaperAD.pdf)
- [SYNGENE INTERNATIONAL LIMITED has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_12953_WebXMLFile_20261029_193554301.xml)
- [Syngene International Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/SYNGENE2_28102026233519_AudioRecordingcoveringletter.pdf)
- [Syngene International Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/SYNGENE2_27102026193349_OutcomeQ2FY27_Signed.pdf)
- [Syngene International Limited has informed the Exchange about change in Management |SUBJECT: Change in Management](https://nsearchives.nseindia.com/corporate/SYNGENE2_27102026201706_SEDisclosureSMPKMP_Signed.pdf)
- [Syngene International Limited has informed the Exchange regarding a press release dated October 27, 2026, titled "Syngene reports sequential revenue growth of 13% in Q2 FY27; Operating EBITDA margin improves by 6 percentage points". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/SYNGENE2_27102026203515_PRQ2FY2027_Signed.pdf)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1747279_27102026092020_WEB.xml)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1747280_27102026092111_WEB.xml)
- [SYNGENE INTERNATIONAL LIMITED has informed the Exchange about Change in Directors/KMP/SMP/Auditor/RTA |SUBJECT: Change in Directors/KMP/SMP/Auditor/RTA](https://nsearchives.nseindia.com/corporate/xbrl/CIM_12953_WebXMLFile_20261027_212343710.xml)

### Fundamentals

Syngene International’s Q2 FY2026-27 results (₹833 crore revenue) show a sequential recovery from Q1’s loss, with net profit turning positive at ₹32.2 crore and EPS of ₹0.8. However, the trailing twelve-month (TTM) picture remains weak: TTM sales have contracted 6% to ₹3,522 crore, while TTM net profit has fallen sharply by 43% to ₹186 crore. Operating profit for the year ended March 2026 declined to ₹921 crore from ₹1,045 crore in the prior year. Earnings quality is mixed; while cash flow from operations improved significantly in FY2025 (₹1,168 crore vs ₹1,042 crore in FY2024), it dropped to ₹915 crore in FY2026. The company’s balance sheet shows reduced borrowings (₹458 crore in Mar 2026 vs ₹578 crore in Mar 2025) but also lower cash reserves (₹120 crore as of Sep 2026 vs ₹327 crore a year earlier). Return on Capital Employed (ROCE) has trended down to 10% in Mar 2026 from 15% in Mar 2024. Institutional ownership has shifted, with DIIs increasing their stake to 29.31% while FIIs reduced theirs to 10.13% by Sep 2026.

key_points": [
    "Q2 FY2026-27 Net Profit: ₹32.2 crore (EPS ₹0.8), recovering from Q1 loss of ₹9 crore.",
    "TTM Performance: Sales -6% (₹3,522 crore); Net Profit -43% (₹186 crore); ROCE 10%.",
    "Cash Position: Cash & Equivalents fell to ₹120 crore (Sep 2026) from ₹327 crore (Sep 2025).",
    "Ownership Shift: DII holding rose to 29.31%; FII holding dropped to 10.13% (Sep 2026)."
]

### Bear Case

Syngene International faces significant headwinds as evidenced by a -52.8% current drawdown from its peak and a maximum drawdown of -60.6%. The stock has underperformed over the long term, with a return since start of -52.8%, a year-to-date decline of -36.1%, and a one-year return of -33.1%. While short-term momentum shows some strength (+14.3% over 1 month), the broader trend remains weak, with the monthly technical indicator signaling a bearish direction. Operationally, the company is undergoing a leadership transition; a new CEO has been appointed to address 'years of operational drift,' but a full turnaround is expected to take several quarters, introducing near-term execution uncertainty.

- Severe historical underperformance: Current drawdown stands at -52.8% against a maximum drawdown of -60.6%; YTD return is -36.1% and 1-year return is -33.1%.
- Operational transition risk: A new CEO is addressing past operational drift, but management indicates a full turnaround will require several quarters.
- Mixed technical signals: Monthly trend is bearish (Supertrend: bearish, ADX: 55.07) despite daily bullishness (Supertrend: bullish, ADX: 32.35).
- Volatility remains elevated: Annualized volatility is +32.9% with an ATR percent of 3.81%, indicating continued price instability.

- [Syngene's new CEO begins cleanup after years of drift, but turnaround could take several quarters](https://www.moneycontrol.com/news/business/syngene-s-new-ceo-begins-cleanup-after-years-of-drift-but-turnaround-could-take-several-quarters-14066083.html)
- [SYNGENE INTERNATIONAL LIMITED has informed the Exchange about Transcripts - earnings or quarterly calls |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_12953_WebXMLFile_20261102_175127374.xml)
- [Syngene International Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/SYNGENE2_29102026190829_SEIntimationNewspaperAD.pdf)
- [SYNGENE INTERNATIONAL LIMITED has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_12953_WebXMLFile_20261029_193554301.xml)
- [Syngene International Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/SYNGENE2_28102026233519_AudioRecordingcoveringletter.pdf)
- [Syngene International Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/SYNGENE2_27102026193349_OutcomeQ2FY27_Signed.pdf)
- [Syngene International Limited has informed the Exchange about change in Management |SUBJECT: Change in Management](https://nsearchives.nseindia.com/corporate/SYNGENE2_27102026201706_SEDisclosureSMPKMP_Signed.pdf)
- [Syngene International Limited has informed the Exchange regarding a press release dated October 27, 2026, titled "Syngene reports sequential revenue growth of 13% in Q2 FY27; Operating EBITDA margin improves by 6 percentage points". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/SYNGENE2_27102026203515_PRQ2FY2027_Signed.pdf)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1747279_27102026092020_WEB.xml)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1747280_27102026092111_WEB.xml)

### FAQs

**What financial results did Syngene report for Q2 FY27, and what significant corporate actions were noted?**

For the quarter ended September 30, 2026, Syngene reported consolidated revenue of ₹8,327 million and profit after tax of ₹322 million. Standalone revenue was ₹7,779 million with a profit after tax of ₹487 million. The Board also noted ongoing voluntary liquidation of subsidiary Syngene Manufacturing Solutions Limited (SMSL) and an asset acquisition in the USA by Syngene USA Inc.

**How is the new leadership addressing past operational issues, and what is the expected timeline for improvement?**

Syngene has appointed a new CEO who is initiating a cleanup process following years of operational drift. Management indicates that a full turnaround is expected to take several quarters, suggesting that near-term financial metrics may continue to reflect this transition period rather than immediate stabilization.

**What are the key technical price levels and recent performance trends for SYNGENE as of November 6, 2026?**

The stock closed at ₹415.25, with immediate resistance at ₹417.65 and support at ₹408.60. While the daily trend shows bullish signals, the monthly and weekly trends remain bearish. Year-to-date returns are -36.1%, and the stock is currently experiencing a drawdown of -52.8% from its maximum peak.

- [Syngene's new CEO begins cleanup after years of drift, but turnaround could take several quarters](https://www.moneycontrol.com/news/business/syngene-s-new-ceo-begins-cleanup-after-years-of-drift-but-turnaround-could-take-several-quarters-14066083.html)
- [SYNGENE INTERNATIONAL LIMITED has informed the Exchange about Transcripts - earnings or quarterly calls |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_12953_WebXMLFile_20261102_175127374.xml)
- [Syngene International Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/SYNGENE2_29102026190829_SEIntimationNewspaperAD.pdf)
- [SYNGENE INTERNATIONAL LIMITED has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_12953_WebXMLFile_20261029_193554301.xml)
- [Syngene International Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/SYNGENE2_28102026233519_AudioRecordingcoveringletter.pdf)
- [Syngene International Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/SYNGENE2_27102026193349_OutcomeQ2FY27_Signed.pdf)
- [Syngene International Limited has informed the Exchange about change in Management |SUBJECT: Change in Management](https://nsearchives.nseindia.com/corporate/SYNGENE2_27102026201706_SEDisclosureSMPKMP_Signed.pdf)
- [Syngene International Limited has informed the Exchange regarding a press release dated October 27, 2026, titled "Syngene reports sequential revenue growth of 13% in Q2 FY27; Operating EBITDA margin improves by 6 percentage points". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/SYNGENE2_27102026203515_PRQ2FY2027_Signed.pdf)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1747279_27102026092020_WEB.xml)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1747280_27102026092111_WEB.xml)
## Technical analytics

- As of: 2026-11-06
- Daily trend: Moderate Uptrend
- Weekly trend: Weak Uptrend
- Pivot point: ₹417.65
- Risk regime: Higher Price Risk

### Support levels
- 405.9
- 396.95
- 387.05

### Resistance levels
- 448.65
- 463.8
- 490.7

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +0.28% |
| return_10 | +13.19% |
| return_1m | +14.33% |
| return_1y | -33.09% |
| return_20 | +20.01% |
| return_3m | +3.88% |
| return_5 | +3.12% |
| return_6m | -7.74% |
| return_since_start | -52.77% |
| return_ytd | -36.14% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | high_risk |
| label | Higher price risk |
| summary | Recent drawdown or price variability is materially high and may lead to larger short-term outcomes. |
| maximum_drawdown | -60.65% |
| annualized_volatility | +32.92% |

## Quarterly financials

- Latest complete quarter: fy27_q2

# Syngene International Limited FY2026-27 Q2: Revenue rebounds, earnings remain below year-ago

Syngene reported consolidated revenue from operations of ₹832.7 crore in FY2026-27 Q2, up 13.1% sequentially, and returned to a profit of ₹32.2 crore after a ₹9 crore loss in Q1. The rebound was incomplete: revenue was 8.6% lower and profit 52% lower than in Q2 FY2025-26, while operating cash flow was negative at ₹143.2 crore.

## Revenue and expenses

Revenue from operations increased from ₹736 crore in Q1 FY2026-27 to ₹832.7 crore in Q2. Total income, including ₹28 crore of other income, rose to ₹860.7 crore from ₹761.3 crore.

Total expenses increased 5.2% sequentially to ₹807 crore from ₹767 crore, slower than revenue growth. Year on year, revenue was down from ₹910.6 crore in Q2 FY2025-26; it was also below the ₹1,036.5 crore reported in Q4 FY2025-26.

## Profitability

Profit before exceptional items and tax was ₹53.7 crore, compared with a ₹5.7 crore loss in Q1 FY2026-27. After an exceptional charge of ₹6.7 crore, versus ₹13.5 crore in Q1, profit before tax was ₹47 crore. Tax expense of ₹14.8 crore left profit for the period at ₹32.2 crore.

Basic EPS was ₹0.80, against a loss per share of ₹0.22 in Q1. Year on year, profit declined from ₹67.1 crore in Q2 FY2025-26. Comprehensive income was ₹42.9 crore, up from ₹26.3 crore in the previous quarter.

## Cash flow and liquidity

Operating cash flow was negative at ₹143.2 crore. Investing cash flow was positive at ₹49.7 crore and financing cash flow was negative at ₹20.3 crore, leaving operating plus investing cash flow negative at ₹93.5 crore.

Cash and cash equivalents stood at ₹119.9 crore on 30 September 2026, down from ₹228.6 crore on 31 March 2026. Current investments were ₹409.3 crore, compared with ₹456.1 crore at the March-end date.

## Working capital and balance sheet

Trade receivables were ₹385.5 crore at 30 September 2026, down from ₹508.8 crore at 31 March 2026. Inventories stood at ₹167.8 crore, up from ₹141.3 crore.

Current liabilities declined to ₹1,182.9 crore from ₹1,552.3 crore at March-end, while other current liabilities fell to ₹467.4 crore from ₹778.3 crore. Total equity was ₹4,858.8 crore and total assets were ₹6,658.5 crore at quarter-end.

## Management commentary

Management attributed the approximately 9% year-on-year revenue decline and Q2 operating EBITDA margin of 18% mainly to lower Zoetis revenues and forex hedge losses. It said the margin would have been in the mid-20s range excluding the hedge loss. CEO Siddharth Mittal cited sequential revenue growth of 13%, supported by CDMO traction, and a 6-percentage-point improvement in operating EBITDA margin from Q1. Management also highlighted the signing of the first manufacturing agreement for the Bayview biologics facility in the U.S. during the quarter.

## Key Takeaway

Q2 marked a sequential recovery in revenue and a return to positive earnings, but both remained below the year-earlier quarter. Negative operating cash flow and lower cash and current investments than at March-end temper the improvement, leaving cash generation an important consideration alongside the operating rebound.

### Ratios

## Shareholding pattern

- Quarter: FY2027-Q1
- As of: 2026-06-30
- Promoter holding: +52.59%
- FII holding: +11.82%
- DII holding: +28.01%
- Mutual fund holding: +25.78%
- Retail holding: +4.77%
- Promoter pledged: +0.00%

### Major reported shareholders

- BIOCON LIMITED — +52.32% (Bodies Corporate)
- NIPPON LIFE INDIA TRUSTEE LTD- A/C NIPPON INDIA FO — +7.73%
- ICICI PRUDENTIAL NIFTY SMALLCAP 250 ETF — +5.30%
- DSP NIFTY SMALLCAP 250 INDEX FUND — +4.61%
- GOVERNMENT OF SINGAPORE — +2.13%
- SBI NIFTY SMALLCAP 250 INDEX FUND — +1.95%
- MIRAE ASSET NIFTY 500 HEALTHCARE ETF — +1.85%
- LIFE INSURANCE CORPORATION OF INDIA — +1.78%
- HSBC MUTUAL FUND - HSBC MIDCAP FUND — +1.55%
- BIOCON LIMITED EMPLOYEE WELFARE TRUST (MURALI KRISHNAN K N and K NANDA KUMAR) — +0.26% (Trusts)

## Official filings

- 2026-11-02 — Generic Announcement: Syngene International Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_12953_WebXMLFile_20261102_175127374.xml)
- 2026-10-29 — Generic Announcement: Syngene International Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SYNGENE2_29102026190829_SEIntimationNewspaperAD.pdf)
- 2026-10-29 — Generic Announcement: Syngene International Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_12953_WebXMLFile_20261029_193554301.xml)
- 2026-10-28 — Generic Announcement: Syngene International Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SYNGENE2_28102026233519_AudioRecordingcoveringletter.pdf)
- 2026-10-27 — Generic Announcement: Syngene International Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SYNGENE2_27102026193349_OutcomeQ2FY27_Signed.pdf)
- 2026-10-27 — Generic Announcement: Syngene International Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SYNGENE2_27102026201706_SEDisclosureSMPKMP_Signed.pdf)
- 2026-10-27 — Press Release: Syngene International Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SYNGENE2_27102026203515_PRQ2FY2027_Signed.pdf)
- 2026-10-27 — Financial Results Filing: Syngene International Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1747279_27102026092020_WEB.xml)
- 2026-10-27 — Financial Results Filing: Syngene International Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1747280_27102026092111_WEB.xml)
- 2026-10-27 — Generic Announcement: Syngene International Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_12953_WebXMLFile_20261027_212343710.xml)
- 2026-10-27 — Management Change: Syngene International Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SYNGENE_ROID_102006_KMP_Doc.zip)
- 2026-10-27 — Earnings Presentation: Syngene International Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SYNGENE2_27102026212955_SEDisclosureIPQ2FY27_Signed.pdf)
- 2026-10-17 — Generic Announcement: Syngene International Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SYNGENE2_17102026184425_Investorcallinitimation_Oct282026_Signed.pdf)
- 2026-10-17 — Generic Announcement: Syngene International Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_12953_WebXMLFile_20261017_185454660.xml)
- 2026-10-08 — Board Meeting Notice: Syngene International Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SYNGENE2_08102026183257_BoardMeetingIntimationOctober272026.pdf)
- 2026-10-08 — Generic Announcement: Syngene International Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_12953_WebXMLFile_20261008_184534190.xml)
- 2026-10-08 — Board Meeting Notice: Syngene International Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_12953_WebXMLFile_20261008_184534190.xml)
- 2026-10-08 — Generic Announcement: Syngene International Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SYNGENE2_08102026185423_SEIntimationRegulation74.pdf)
- 2026-09-25 — Generic Announcement: Syngene International Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SYNGENE2_25092026172018_Tradingwindowclosureintimation25092026.pdf)
- 2026-09-25 — Generic Announcement: Syngene International Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_12953_WebXMLFile_20260925_172745459.xml)
- 2026-09-24 — Generic Announcement: Syngene International Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SYNGENE2_24092026114740_24092026Cancelled.pdf)
- 2026-09-21 — Generic Announcement: Syngene International Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SYNGENE2_21092026174336_Investorcallintimation24September2026.pdf)
- 2026-09-21 — Generic Announcement: Syngene International Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_12953_WebXMLFile_20260921_175715059.xml)
- 2026-09-21 — Management Change: Syngene International Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SYNGENE2_21092026224924_SEDisclosure_Sept212026.pdf)
- 2026-09-21 — Management Change: Syngene International Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SYNGENE_ROID_98731_KMP_Doc.zip)

## News and market events

- 2026-11-02 — MONEYCONTROL: **Syngene's new CEO begins cleanup after years of drift, but turnaround could take several quarters** — Syngene has appointed a new CEO who is beginning a cleanup process following years of operational drift, with a full turnaround expected to take several quarters. — [Source](https://www.moneycontrol.com/news/business/syngene-s-new-ceo-begins-cleanup-after-years-of-drift-but-turnaround-could-take-several-quarters-14066083.html)
- 2026-10-28 — Mint: **Syngene International shares surge 12%, biggest 1-day gain in 6 years; what drove the rally despite a Q2 profit drop? | Stock Market News** — Syngene International shares surged 12% after the company reported a sequential turnaround in September-quarter profit, rising to ₹32.2 crore from a June-quarter loss. — [Source](https://www.livemint.com/market/stock-market-news/syngene-international-shares-surge-12-biggest-1-day-gain-in-6-years-what-drove-the-rally-despite-a-q2-profit-drop-11793186513787.html)
- 2026-10-28 — FEEDS: **Stock Market Live: Sensex Down 300 Points, Nifty Near 22,700; Syngene Zooms 11%, MRPL Tanks 9%** — Stock Market LIVE Updates: Barring Nifty Auto, all other sectoral indices were trading in the red, with Nifty IT falling the most over 3%, followed by Nifty FMCG, Nifty Oil & Gas, Nifty Realty, Nifty Metals and Nifty Pharma. — [Source](https://www.ndtvprofit.com/markets/stock-market-live-updates-gift-nifty-live-updates-today-sensex-today-nifty50-jio-platforms-ipo-listing-q2-earnings-brent-crude-october-28-2026-12246212)
- 2026-10-28 — FREEPRESSJOURNAL.IN: **Syngene International Reports Strong Q2 FY27 Performance With 13% Sequential Revenue Growth And Improved EBITDA Margins** — Syngene International Ltd reported a 13% sequential increase in revenue from operations for the second quarter of fiscal year 2027. The company — [Source](https://www.freepressjournal.in/business/syngene-international-reports-strong-q2-fy27-performance-with-13-sequential-revenue-growth-and-improved-ebitda-margins)
- 2026-10-27 — CNBC-TV18: **Stocks to Watch for October 28: Jio Platforms, TATA Capital, Infosys, AWL Agri and more** — From Tata Capital, AWL Agri Business and Vedanta Iron & Steel reporting their Q2 results to Jio Platforms making its market debut tomorrow, here are the stocks to watch in Wednesday’s trading session. — [Source](https://www.cnbctv18.com/photos/market/stocks-to-watch-for-october-28-jio-platforms-listing-price-tata-capital-infosys-awl-agri-and-more-20020516.htm)
- 2026-10-11 — BUSINESSTODAY: **Indian pharma leaders seek faster trials, state-backed market for new drugs** — Indian pharmaceutical industry, innovative medicines India, clinical trials India, pharma regulatory challenges, Sun Pharma Organon acquisition, Glenmark AbbVie deal, pharma R&D investment, Indian pharma global expansion, IFQM Symposium 2026, pharma market access India — [Source](https://www.businesstoday.in/industry/pharma/story/indian-pharma-leaders-seek-faster-trials-state-backed-market-for-new-drugs-560883-2026-10-11)
- 2026-08-27 — MONEYCONTROL: **Goldman Sachs-backed CRDMO Aragen Life Sciences files IPO papers to raise Rs 800 crore fresh capital** — Aragen Life Sciences IPO size,Aragen Life Sciences IPO DRHP,Aragen Life Sciences IPO news,Aragen Life Sciences IPO details,Goldman Sachs — [Source](https://www.moneycontrol.com/news/business/ipo/goldman-sachs-backed-crdmo-aragen-life-sciences-files-ipo-papers-to-raise-rs-800-crore-fresh-capital-14017035.html)
- 2026-08-13 — MONEYCONTROL: **Kenneth Andrade-backed Old Bridge MF adds Jubilant FoodWorks, Redington, Delhivery; exits Axis Bank, Syngene International** — Old Bridge MF, Kenneth Andrade — [Source](https://www.moneycontrol.com/news/business/markets/kenneth-andrade-backed-old-bridge-mf-adds-jubilant-foodworks-redington-delhivery-exits-axis-bank-syngene-international-14004150.html)
- 2026-07-30 — CNBC-TV18: **Sensex Today | Stock Market LIVE Updates: Nifty back above 24,250; KPIT Tech shares decline over 7%** — Sensex Today | Stock Market LIVE Updates: Today is the monthly expiry of the Sensex contracts. 24,000 on the downside will be key for the Nifty, while the July 17 high of 24,367 will be the first hurdle to cross on the upside. The Nifty Bank has taken a backseat after the IT outperformance, but it remains to be seen whether IT could hold fort for another day today. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-expiry-infosys-it-eicher-dabur-vedanta-irfc-asian-paints-share-price-liveblog-19957305.htm)
- 2026-07-30 — CNBC-TV18: **The biggest movers on the Nifty 500 index today** — From strong Q1 earnings beats to margin pressures, here's a complete look at what drove today's biggest Nifty 500 movers and how each stock stacks up against its 52-week levels. Check out which stocks were moving the Nifty 500 at market open today. — [Source](https://www.cnbctv18.com/photos/market/nifty-500-top-gainers-losers-redington-balkrishna-syrma-gallant-wipro-hexaware-syngene-waaree-19957530.htm)
- 2026-07-30 — CNBC-TV18: **Syngene shares down 8% after Q1 results disappointment, revenue outlook cut** — Management expects the first half of FY27 to remain challenging, with Syngene's revenue likely to decline during the period. However, it anticipates business momentum to improve in the second half, which should partly offset the weak first-half performance. — [Source](https://www.cnbctv18.com/market/syngene-shares-in-focus-after-q1-results-disappointment-revenue-outlook-cut-19957401.htm)
- 2026-07-30 — CNBC-TV18: **Q1 Results LIVE Updates: Eicher Motors target price raised; MTAR Tech up 5%, M&M reports today** — Q1 Results LIVE Updates: Bajaj Finance, M&M and Tata Steel are the three Nifty results for the day, along with broader market names like Hyundai Motor, Vedanta, Vedanta Aluminium, Swiggy, Mazagon Dock, Torrent Pharma, Thermax and many others. Eicher Motors, Dabur, three Vedanta demerged units, Bajaj Housing, Hexaware and many more also react to numbers. Watch this space for all the LIVE Q1 results updates. — [Source](https://www.cnbctv18.com/market/q1-results-live-updates-today-bajaj-finance-mm-tata-steel-eicher-dabur-mazagon-dock-swiggy-syngene-irfc-vedanta-aluminium-mtar-hyundai-lic-liveblog-19957385.htm)

## Business profile

**Strategic vision:** Integrated scientific services for drug discovery and development.

### Business segments
- **Discovery Services:** These services span early-stage research from target identification to the delivery of drug candidates for further development, employing a target-focused, modality- and therapeutic area-agnostic approach.
- **Development Services:** Syngene offers robust and scalable Chemical Development services, involving route scouting for complex APIs, method development, and cGMP manufacturing.
- **Manufacturing Services:** Syngene undertakes cGMP manufacturing for both small molecules and biologics, providing solutions from GLP-Tox batches to clinical supplies, scale-up, launch, and commercial manufacturing.

### Competitive strengths
- Offers integrated scientific services across the entire drug discovery and development value chain.
- Provides customized end-to-end solutions for R&D and manufacturing requirements.
- Focuses on collaborative partnerships and integrated collaborations.

## Related stocks

- [Acutaas Chemicals Limited (Healthcare)](https://faxioms.com/stocks/acutaas) — +0.30%
- [Blue Jet Healthcare Limited (Healthcare)](https://faxioms.com/stocks/bluejet) — -3.23%
- [Caplin Point Laboratories Limited (Healthcare)](https://faxioms.com/stocks/caplipoint) — -1.64%
- [Cohance Lifesciences Limited (Healthcare)](https://faxioms.com/stocks/cohance) — -3.56%
- [Concord Biotech Limited (Healthcare)](https://faxioms.com/stocks/concordbio) — -6.64%

## Freshness and sources

- Data as of: 2026-11-06
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/syngene
Markdown representation: https://faxioms.com/stocks/syngene?render=md